Study of an injected biologic for moderate to severe atopic dermatitis
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injectable medication called MG-K10 for people with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces itching and clears skin better than a placebo. If you've tried topical treatments without enough relief, this might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have had atopic dermatitis for at least 1 year.
- Your current treatment (like creams or ointments) hasn't worked well enough, or you can't use them due to side effects.
- You haven't used certain other eczema medications (like biologics or JAK inhibitors) within a specific time frame.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
This study tests a new injected medication called XKH001 for people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't improved with standard creams. The goal is to see if it can reduce the severity of eczema and itching.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This study tests an injection called ADSTEM for people with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams or other treatments. The goal is to see if it can help reduce symptoms like itching and rash.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.